-

06:02:21 PM

NVRO Stock News

NVRO - Nevro Corp

01/19/23 7:00 AM

NYSE : NVRO

conferencesearnings

Nevro to Report Fourth Quarter and Full-Year 2022 Financial Results

A live webcast of this event, as well as an archived recording, will be available in the Investors section of Nevro's website at www.nevro.com. Nevro routinely posts information that may be important to investors in the "Investor Relations" section of its website at www.nevro.com. The company encourages investors and potential investors to consult the Nevro...

RHEA-AI

neutral

01/12/23 7:00 AM

NYSE : NVRO

Nevro to Highlight New Clinical Evidence at the 2023 North American Neuromodulation Society (NANS) 26th Annual Meeting

Nevro Corp. (NYSE: NVRO), a global medical device company delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced a series of data presentations supporting the use of the company's HFX™ 10 kHz Therapy

RHEA-AI

neutral

01/09/23 6:00 AM

NYSE : NVRO

Nevro Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2022 Revenue and Provides Full-Year 2023 Revenue Guidance

Nevro Corp. (NYSE: NVRO),

RHEA-AI

positive

12/19/22 4:05 PM

NYSE : NVRO

conferences

Nevro to Present at 41st Annual J.P. Morgan Healthcare Conference

Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that D.

RHEA-AI

neutral

12/14/22 7:00 AM

NYSE : NVRO

clinical trial

Nevro Announces Two Presentations from SENZA-PDN and SENZA-NSRBP Clinical Trials Have Been Accepted for Late-Breaking Abstract Sessions at NANS 2023 Annual Meeting

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive,

RHEA-AI

neutral

11/02/22 4:05 PM

NYSE : NVRO

earnings

Nevro Reports Third Quarter 2022 Financial Results, Narrows Full-Year 2022 Guidance and Raises Revenue Contribution from Painful Diabetic Neuropathy

Nevro Corp. (NYSE: NVRO), delivering comprehensive, life-changing solutions for the treatment of chronic pain, today reported its financial results for the third quarter ended September 30, 2022, narrowed its full-year 2022 guidance and raised its

RHEA-AI

positive

10/12/22 6:13 PM

NYSE : NVRO

fda approval

Nevro Announces FDA Approval of HFX iQ™ Spinal Cord Stimulation System to Personalize the Treatment of Chronic Pain

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering

RHEA-AI

very positive

10/10/22 7:00 AM

NYSE : NVRO

Nevro Comments on UnitedHealthcare Medical Coverage Policy Update

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that on October 1, 2022, UnitedHealthcare ("United") released an update to its

RHEA-AI

neutral

10/05/22 7:00 AM

NYSE : NVRO

conferencesearnings

Nevro to Report Third Quarter 2022 Financial Results

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today

RHEA-AI

neutral

10/04/22 4:05 PM

NYSE : NVRO

fda approval

Nevro Announces FDA Approval of Costa Rica Manufacturing Operations

Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, announced today that the U.S. Food and Drug Administration (FDA) has approved its manufacturing

RHEA-AI

very positive

1 2 3 4 5 6 7 8 9 Next

NVRO Data

IndustrySurgical and Medical Instrument Manufacturing
Websitewww.nevro.com
CeoD.Keith Grossman
Security nameNevro Corp
Issue typecs
SectorManufacturing
Sic code3841
Employees843
Tags
- Health Technology
- Medical Specialties
- Manufacturing
- Surgical and Medical Instrument Manufacturing
Address1800 Bridge Pkwy
StateCalifornia
CityRedwood City
Zip94065-1164
CountryUS
Phone16502510005

About Nevro Corp

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.